Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin | Zendy

Willeke de Haan | Zendy; Jitske de Vries-van der Weij | Zendy; José W.A. van der Hoorn | Zendy; Thomas Gautier | Zendy; Caroline C. van der Hoogt | Zendy; Marit Westerterp | Zendy; Johannes A. Romijn | Zendy; J. Wouter Jukema | Zendy; Louis M. Havekes | Zendy; P. Hans | Zendy; Patrick C.N. Rensen | Zendy

Open Access

Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin

Author(s) -

Willeke de Haan,

Jitske de Vries-van der Weij,

José W.A. van der Hoorn,

Thomas Gautier,

Caroline C. van der Hoogt,

Marit Westerterp,

Johannes A. Romijn,

J. Wouter Jukema,

Louis M. Havekes,

P. Hans,

Patrick C.N. Rensen

Publication year - 2008

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.107.761965

Subject(s) - atorvastatin , cholesterylester transfer protein , medicine , endocrinology , cholesterol , lipoprotein

Although cholesteryl ester transfer protein (CETP) inhibition is regarded as a promising strategy to reduce atherosclerosis by increasing high-density lipoprotein cholesterol, the CETP inhibitor torcetrapib given in addition to atorvastatin had no effect on atherosclerosis and even increased cardiovascular death in the recent Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial. Therefore, we evaluated the antiatherogenic potential and adverse effects of torcetrapib in humanized APOE*3-Leiden.CETP (E3L.CETP) mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research